Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,32393496,time to normalization of respiratory function,"Compared to placebo+OTV, MHAA4549A+OTV did not significantly reduce the time to normalization of respiratory function (placebo+OTV, 4.28 days; 3,600 mg MHAA4549A+OTV, 2.78 days; 8,400 mg MHAA4549A+OTV, 2.65 days), nor did it improve other secondary clinical outcomes.","A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial of MHAA4549A, a Monoclonal Antibody, plus Oseltamivir in Patients Hospitalized with Severe Influenza A Virus Infection. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32393496/),d,4.28,120,DB00198,Oseltamivir
,32393496,time to normalization of respiratory function,"Compared to placebo+OTV, MHAA4549A+OTV did not significantly reduce the time to normalization of respiratory function (placebo+OTV, 4.28 days; 3,600 mg MHAA4549A+OTV, 2.78 days; 8,400 mg MHAA4549A+OTV, 2.65 days), nor did it improve other secondary clinical outcomes.","A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial of MHAA4549A, a Monoclonal Antibody, plus Oseltamivir in Patients Hospitalized with Severe Influenza A Virus Infection. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32393496/),d,2.78,121,DB00198,Oseltamivir
,32393496,time to normalization of respiratory function,"Compared to placebo+OTV, MHAA4549A+OTV did not significantly reduce the time to normalization of respiratory function (placebo+OTV, 4.28 days; 3,600 mg MHAA4549A+OTV, 2.78 days; 8,400 mg MHAA4549A+OTV, 2.65 days), nor did it improve other secondary clinical outcomes.","A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial of MHAA4549A, a Monoclonal Antibody, plus Oseltamivir in Patients Hospitalized with Severe Influenza A Virus Infection. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32393496/),d,2.65,122,DB00198,Oseltamivir
,27167096,IC50,"Among these phosphonate compounds, the dehydration derivative 7a that has a relatively rigid cyclopentene core structure exhibits the strongest inhibitory activity (IC50 = 0.3-4.1 nM) against several NAs of wild-type human and avian influenza viruses (H1N1, H3N2, H5N1, and H7N9), although the phosphonate congener 6a is unexpectedly less active than peramivir.",Peramivir Phosphonate Derivatives as Influenza Neuraminidase Inhibitors. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27167096/),nM,0.3-4.1,10481,DB00198,Oseltamivir
,27167096,IC50,Compound 7a is active to the oseltamivir-resistant H275Y strains of H1N1 and H5N1 viruses (IC50 = 73-86 nM).,Peramivir Phosphonate Derivatives as Influenza Neuraminidase Inhibitors. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27167096/),nM,73-86,10482,DB00198,Oseltamivir
,27167096,EC50,"The phosphonate monoalkyl esters (6b, 6c, 7b, 7c, 8b, and 8c) are better anti-influenza agents (EC50 = 19-89 nM) than their corresponding phosphonic acids (EC50 = 50-343 nM) in protection of cells from the viral infection.",Peramivir Phosphonate Derivatives as Influenza Neuraminidase Inhibitors. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27167096/),nM,19-89,10483,DB00198,Oseltamivir
,27167096,EC50,"The phosphonate monoalkyl esters (6b, 6c, 7b, 7c, 8b, and 8c) are better anti-influenza agents (EC50 = 19-89 nM) than their corresponding phosphonic acids (EC50 = 50-343 nM) in protection of cells from the viral infection.",Peramivir Phosphonate Derivatives as Influenza Neuraminidase Inhibitors. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27167096/),nM,50-343,10484,DB00198,Oseltamivir
,23056234,mother-to-fetus transfer ratio,"The data demonstrated that the mother-to-fetus transfer ratio of OSE and OCA were 1.64 and 0.019, respectively, suggesting that OSE, but not OCA, penetrated through the placenta.",Chemical analysis and transplacental transfer of oseltamivir and oseltamivir carboxylic acid in pregnant rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23056234/),,1.64,17845,DB00198,Oseltamivir
,23056234,mother-to-fetus transfer ratio,"The data demonstrated that the mother-to-fetus transfer ratio of OSE and OCA were 1.64 and 0.019, respectively, suggesting that OSE, but not OCA, penetrated through the placenta.",Chemical analysis and transplacental transfer of oseltamivir and oseltamivir carboxylic acid in pregnant rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23056234/),,0.019,17846,DB00198,Oseltamivir
,21930881,area under the concentration-time curve for the dosing interval (AUC(0-τ)),"Similar to previous pharmacokinetic analyses in nonobese subjects, the mean (percent covariance [CV]) area under the concentration-time curve for the dosing interval (AUC(0-τ)) was 2,621 ng · h/ml (17) for oseltamivir carboxylate.",Oseltamivir and oseltamivir carboxylate pharmacokinetics in obese adults: dose modification for weight is not necessary. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21930881/),[h·ng] / [ml],"2,621",27922,DB00198,Oseltamivir
,18923671,AUC(0-12),"Corresponding AUC(0-12) values (5932, 10,951 and 34,670 ng.h/ml) and trough OC concentrations (376, 575 and 2730 ng/ml) were higher than previously reported in healthy volunteers; the latter exceeded 545 to 3956 fold the H5N1 IC(50) (0.69 ng/ml) isolated from the H5N1 infected female.",Oseltamivir is adequately absorbed following nasogastric administration to adult patients with severe H5N1 influenza. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18923671/),[h·ng] / [ml],5932,29488,DB00198,Oseltamivir
,18923671,AUC(0-12),"Corresponding AUC(0-12) values (5932, 10,951 and 34,670 ng.h/ml) and trough OC concentrations (376, 575 and 2730 ng/ml) were higher than previously reported in healthy volunteers; the latter exceeded 545 to 3956 fold the H5N1 IC(50) (0.69 ng/ml) isolated from the H5N1 infected female.",Oseltamivir is adequately absorbed following nasogastric administration to adult patients with severe H5N1 influenza. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18923671/),[h·ng] / [ml],"10,951",29489,DB00198,Oseltamivir
,18923671,AUC(0-12),"Corresponding AUC(0-12) values (5932, 10,951 and 34,670 ng.h/ml) and trough OC concentrations (376, 575 and 2730 ng/ml) were higher than previously reported in healthy volunteers; the latter exceeded 545 to 3956 fold the H5N1 IC(50) (0.69 ng/ml) isolated from the H5N1 infected female.",Oseltamivir is adequately absorbed following nasogastric administration to adult patients with severe H5N1 influenza. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18923671/),[h·ng] / [ml],"34,670",29490,DB00198,Oseltamivir
,18923671,trough OC concentrations,"Corresponding AUC(0-12) values (5932, 10,951 and 34,670 ng.h/ml) and trough OC concentrations (376, 575 and 2730 ng/ml) were higher than previously reported in healthy volunteers; the latter exceeded 545 to 3956 fold the H5N1 IC(50) (0.69 ng/ml) isolated from the H5N1 infected female.",Oseltamivir is adequately absorbed following nasogastric administration to adult patients with severe H5N1 influenza. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18923671/),[ng] / [ml],376,29491,DB00198,Oseltamivir
,18923671,trough OC concentrations,"Corresponding AUC(0-12) values (5932, 10,951 and 34,670 ng.h/ml) and trough OC concentrations (376, 575 and 2730 ng/ml) were higher than previously reported in healthy volunteers; the latter exceeded 545 to 3956 fold the H5N1 IC(50) (0.69 ng/ml) isolated from the H5N1 infected female.",Oseltamivir is adequately absorbed following nasogastric administration to adult patients with severe H5N1 influenza. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18923671/),[ng] / [ml],575,29492,DB00198,Oseltamivir
,18923671,trough OC concentrations,"Corresponding AUC(0-12) values (5932, 10,951 and 34,670 ng.h/ml) and trough OC concentrations (376, 575 and 2730 ng/ml) were higher than previously reported in healthy volunteers; the latter exceeded 545 to 3956 fold the H5N1 IC(50) (0.69 ng/ml) isolated from the H5N1 infected female.",Oseltamivir is adequately absorbed following nasogastric administration to adult patients with severe H5N1 influenza. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18923671/),[ng] / [ml],2730,29493,DB00198,Oseltamivir
,18923671,IC(50),"Corresponding AUC(0-12) values (5932, 10,951 and 34,670 ng.h/ml) and trough OC concentrations (376, 575 and 2730 ng/ml) were higher than previously reported in healthy volunteers; the latter exceeded 545 to 3956 fold the H5N1 IC(50) (0.69 ng/ml) isolated from the H5N1 infected female.",Oseltamivir is adequately absorbed following nasogastric administration to adult patients with severe H5N1 influenza. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18923671/),[ng] / [ml],0.69,29494,DB00198,Oseltamivir
,22116989,sieving coefficient,A sieving coefficient of approximately 0.9 was identified.,Pharmacokinetic assessment of peramivir in a hospitalized adult undergoing continuous venovenous hemofiltration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22116989/),,0.9,30060,DB00198,Oseltamivir
,24636040,area under the concentration-time curve [AUC],"After the dose was determined, a low dose study (n = 10) was performed, and the optimal dose required to reach the hypothetical target OC exposure (area under the concentration-time curve [AUC] of 60,000 ng · hr/mL) was simulated using a nonparametric superposition method.",Dose selection method for pharmacokinetic study in hemodialysis patients using a subpharmacological dose: oseltamivir as a model drug. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24636040/),[h·ng] / [ml],"60,000",36706,DB00198,Oseltamivir
,25289522,Metabolite clearance,"Metabolite clearance by CCPD [0.32 l h(-1) (70 kg)(-1) ] was 1.9-fold faster than via CAPD [0.17 l h(-1) (70 kg)(-1) ], with renal elimination being dominant in patients with residual urine production.",Pharmacokinetics and safety of oseltamivir in patients with end-stage renal disease treated with automated peritoneal dialysis. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25289522/),[l] / [h],0.32,38803,DB00198,Oseltamivir
,25289522,Metabolite clearance,"Metabolite clearance by CCPD [0.32 l h(-1) (70 kg)(-1) ] was 1.9-fold faster than via CAPD [0.17 l h(-1) (70 kg)(-1) ], with renal elimination being dominant in patients with residual urine production.",Pharmacokinetics and safety of oseltamivir in patients with end-stage renal disease treated with automated peritoneal dialysis. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25289522/),[l] / [h],0.17,38804,DB00198,Oseltamivir
,23436258,elimination half-life (t(1/2) β),"Oseltamivir shows dose linear kinetics, and oseltamivir carboxylate has an elimination half-life (t(1/2) β) after oral administration in healthy individuals of approximately 7.7 hours.",Pharmacokinetic properties of anti-influenza neuraminidase inhibitors. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23436258/),h,7.7,44925,DB00198,Oseltamivir
,23436258,t(1/2) β,Zanamivir distributes in an apparent volume of distribution approximating that of extracellular water and is rapidly eliminated (t(1/2) β of approximately 3.0 hours).,Pharmacokinetic properties of anti-influenza neuraminidase inhibitors. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23436258/),h,3.0,44926,DB00198,Oseltamivir
,23436258,t(1/2) β,Peramivir is slowly eliminated (t(1/2) β of 7.7-20.8 hours) and is prescribed as either a once-daily injection or as a single infusion.,Pharmacokinetic properties of anti-influenza neuraminidase inhibitors. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23436258/),h,7.7-20.8,44927,DB00198,Oseltamivir
,9517946,oral bioavailability,Both parent compounds and the prodrug of the guanidino analog exhibited poor oral bioavailability (2 to 4%) and low peak concentrations in plasma (Cmaxs; Cmax <0.06 microg/ml).,Identification of GS 4104 as an orally bioavailable prodrug of the influenza virus neuraminidase inhibitor GS 4071. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9517946/),%,2 to 4,51019,DB00198,Oseltamivir
<,9517946,Cmax,Both parent compounds and the prodrug of the guanidino analog exhibited poor oral bioavailability (2 to 4%) and low peak concentrations in plasma (Cmaxs; Cmax <0.06 microg/ml).,Identification of GS 4104 as an orally bioavailable prodrug of the influenza virus neuraminidase inhibitor GS 4071. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9517946/),[μg] / [ml],0.06,51020,DB00198,Oseltamivir
,9517946,oral bioavailability,"In contrast, GS 4104, the ethyl ester prodrug of GS 4071, exhibited good oral bioavailability (35%) as GS 4071 and high Cmaxs of GS 4071 (Cmax = 0.47 microg/ml) which are 150 times the concentration necessary to inhibit influenza virus neuraminidase activity by 90%.",Identification of GS 4104 as an orally bioavailable prodrug of the influenza virus neuraminidase inhibitor GS 4071. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9517946/),%,35,51021,DB00198,Oseltamivir
,9517946,Cmax,"In contrast, GS 4104, the ethyl ester prodrug of GS 4071, exhibited good oral bioavailability (35%) as GS 4071 and high Cmaxs of GS 4071 (Cmax = 0.47 microg/ml) which are 150 times the concentration necessary to inhibit influenza virus neuraminidase activity by 90%.",Identification of GS 4104 as an orally bioavailable prodrug of the influenza virus neuraminidase inhibitor GS 4071. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9517946/),[μg] / [ml],0.47,51022,DB00198,Oseltamivir
,9517946,bioavailability,"The bioavailability of GS 4104 as GS 4071 was also determined in mice (30%), ferrets (11%), and dogs (73%).",Identification of GS 4104 as an orally bioavailable prodrug of the influenza virus neuraminidase inhibitor GS 4071. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9517946/),%,30,51023,DB00198,Oseltamivir
,9517946,bioavailability,"The bioavailability of GS 4104 as GS 4071 was also determined in mice (30%), ferrets (11%), and dogs (73%).",Identification of GS 4104 as an orally bioavailable prodrug of the influenza virus neuraminidase inhibitor GS 4071. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9517946/),%,11,51024,DB00198,Oseltamivir
,9517946,bioavailability,"The bioavailability of GS 4104 as GS 4071 was also determined in mice (30%), ferrets (11%), and dogs (73%).",Identification of GS 4104 as an orally bioavailable prodrug of the influenza virus neuraminidase inhibitor GS 4071. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9517946/),%,73,51025,DB00198,Oseltamivir
,16940405,time to maximum plasma concentration (tmax),"The time to maximum plasma concentration (tmax) for oseltamivir was delayed in the very elderly compared with the young subjects (2.30 vs 0.71 h, respectively).",Pharmacokinetics of oseltamivir in young and very elderly subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16940405/),h,2.30,51829,DB00198,Oseltamivir
,16940405,time to maximum plasma concentration (tmax),"The time to maximum plasma concentration (tmax) for oseltamivir was delayed in the very elderly compared with the young subjects (2.30 vs 0.71 h, respectively).",Pharmacokinetics of oseltamivir in young and very elderly subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16940405/),h,0.71,51830,DB00198,Oseltamivir
,17409647,maximum concentration,Oral administration of oseltamivir of 2 mg/kg body weight of oseltamivir to horses provided a plasma concentration of OC (mean maximum concentration: 257.9 ng/ml) above the inhibitory concentrations against equine influenza A viruses determined in vitro.,Clinical pharmacokinetics of oseltamivir and its active metabolite oseltamivir carboxylate after oral administration in horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17409647/),[ng] / [ml],257.9,56665,DB00198,Oseltamivir
,17409647,elimination half-life,"However, because OC is rapidly eliminated from horse plasma (mean elimination half-life: 2.5 hr), administration intervals should be less than 10 hr to retain a suitable concentration when using a single dose of 2 mg/kg oseltamivir.",Clinical pharmacokinetics of oseltamivir and its active metabolite oseltamivir carboxylate after oral administration in horses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17409647/),h,2.5,56666,DB00198,Oseltamivir
,33065127,Log D,"Log D values of oseltamivir and analogues (2.0 to 4.9) were higher than that of oseltamivir acid (0.7), supporting the previous development of oseltamivir to improve permeability of oseltamivir acid.",Systematic Approach for Screening of Prodrugs: Evaluation Using Oseltamivir Analogues as Models. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33065127/),,2.0 to 4.9,70214,DB00198,Oseltamivir
,33065127,Log D,"Log D values of oseltamivir and analogues (2.0 to 4.9) were higher than that of oseltamivir acid (0.7), supporting the previous development of oseltamivir to improve permeability of oseltamivir acid.",Systematic Approach for Screening of Prodrugs: Evaluation Using Oseltamivir Analogues as Models. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33065127/),,0.7,70215,DB00198,Oseltamivir
over,33065127,Solubilities,"Solubilities of analogues in artificial intestinal fluids were over 80%, except the compound with the highest lipophilicity.",Systematic Approach for Screening of Prodrugs: Evaluation Using Oseltamivir Analogues as Models. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33065127/),%,80,70216,DB00198,Oseltamivir
,32621543,clearance,"Mean MHAA4549A clearance was 288-350 mL/day, and mean half-life was 17.8-19.0 days.",Pharmacokinetics of the Monoclonal Antibody MHAA4549A Administered in Combination With Oseltamivir in Patients Hospitalized With Severe Influenza A Infection. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32621543/),[ml] / [d],288-350,73035,DB00198,Oseltamivir
,32621543,half-life,"Mean MHAA4549A clearance was 288-350 mL/day, and mean half-life was 17.8-19.0 days.",Pharmacokinetics of the Monoclonal Antibody MHAA4549A Administered in Combination With Oseltamivir in Patients Hospitalized With Severe Influenza A Infection. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32621543/),d,17.8-19.0,73036,DB00198,Oseltamivir
,10628898,absolute bioavailability,The absolute bioavailability of the active metabolite from orally administered oseltamivir is 80%.,Clinical pharmacokinetics of the prodrug oseltamivir and its active metabolite Ro 64-0802. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10628898/),%,80,74584,DB00198,Oseltamivir
,10628898,apparent half-life,"After peak plasma concentrations are attained, the concentration of the active metabolite declines with an apparent half-life of 6 to 10 hours.",Clinical pharmacokinetics of the prodrug oseltamivir and its active metabolite Ro 64-0802. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10628898/),h,6 to 10,74585,DB00198,Oseltamivir
,32604406,Time-to-influenza symptom resolution,Time-to-influenza symptom resolution was numerically shorter with pimodivir (72.45 hours) than placebo (94.15 hours).,A Phase 2 Study of Pimodivir (JNJ-63623872) in Combination with Oseltamivir in Elderly and NonElderly Adults Hospitalized with Influenza A Infection: OPAL study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32604406/),h,72.45,78054,DB00198,Oseltamivir
,32604406,Time-to-influenza symptom resolution,Time-to-influenza symptom resolution was numerically shorter with pimodivir (72.45 hours) than placebo (94.15 hours).,A Phase 2 Study of Pimodivir (JNJ-63623872) in Combination with Oseltamivir in Elderly and NonElderly Adults Hospitalized with Influenza A Infection: OPAL study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32604406/),h,94.15,78055,DB00198,Oseltamivir
,12392584,bioavailability,"The bioavailability (90% confidence intervals) of Ro 64-0802 following administration of oseltamivir together with Maalox suspension vs administration of oseltamivir alone, was 90% (83.6, 96.9%) for C(max) and 94.1% (91.4, 96.9%) for AUC(0, infinity); similarly, for Titralac tablets, the equivalent values were 95.1% (88.3, 102%) for C(max) and 94.7% (91.9, 97.5%) for AUC(0, infinity).",Lack of pharmacokinetic interaction between the oral anti-influenza neuraminidase inhibitor prodrug oseltamivir and antacids. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12392584/),%,90,78477,DB00198,Oseltamivir
,12392584,bioavailability,"The bioavailability (90% confidence intervals) of Ro 64-0802 following administration of oseltamivir together with Maalox suspension vs administration of oseltamivir alone, was 90% (83.6, 96.9%) for C(max) and 94.1% (91.4, 96.9%) for AUC(0, infinity); similarly, for Titralac tablets, the equivalent values were 95.1% (88.3, 102%) for C(max) and 94.7% (91.9, 97.5%) for AUC(0, infinity).",Lack of pharmacokinetic interaction between the oral anti-influenza neuraminidase inhibitor prodrug oseltamivir and antacids. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12392584/),%,94.1,78478,DB00198,Oseltamivir
,12392584,bioavailability,"The bioavailability (90% confidence intervals) of Ro 64-0802 following administration of oseltamivir together with Maalox suspension vs administration of oseltamivir alone, was 90% (83.6, 96.9%) for C(max) and 94.1% (91.4, 96.9%) for AUC(0, infinity); similarly, for Titralac tablets, the equivalent values were 95.1% (88.3, 102%) for C(max) and 94.7% (91.9, 97.5%) for AUC(0, infinity).",Lack of pharmacokinetic interaction between the oral anti-influenza neuraminidase inhibitor prodrug oseltamivir and antacids. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12392584/),%,95.1,78479,DB00198,Oseltamivir
,12392584,bioavailability,"The bioavailability (90% confidence intervals) of Ro 64-0802 following administration of oseltamivir together with Maalox suspension vs administration of oseltamivir alone, was 90% (83.6, 96.9%) for C(max) and 94.1% (91.4, 96.9%) for AUC(0, infinity); similarly, for Titralac tablets, the equivalent values were 95.1% (88.3, 102%) for C(max) and 94.7% (91.9, 97.5%) for AUC(0, infinity).",Lack of pharmacokinetic interaction between the oral anti-influenza neuraminidase inhibitor prodrug oseltamivir and antacids. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12392584/),%,94.7,78480,DB00198,Oseltamivir
,22105586,Cl,"Of 19 volunteers, 12 were men, with age (mean ± SD) 46 ± 11 years, weight 83 ± 19 kg, and calculated Cl(creatinine) 64 ± 27 mL/min.","Oseltamivir, an influenza neuraminidase inhibitor drug, does not affect the steady-state pharmacokinetic characteristics of cyclosporine, mycophenolate, or tacrolimus in adult renal transplant patients. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22105586/),,64,79249,DB00198,Oseltamivir
,20923248,bioavailability,"According to the currently available literature, the pharmacokinetics of oseltamivir carboxylate after oral administration of oseltamivir are characterized by mean ± SD bioavailability of 79 ± 12%, apparent clearance of 25.3 ± 7.0 L/h, an elimination half-life of 7.4 ± 2.5 hours and an apparent terminal volume of distribution of 267 ± 122 L.","Oseltamivir in seasonal, avian H5N1 and pandemic 2009 A/H1N1 influenza: pharmacokinetic and pharmacodynamic characteristics. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20923248/),%,79,84462,DB00198,Oseltamivir
,20923248,apparent clearance,"According to the currently available literature, the pharmacokinetics of oseltamivir carboxylate after oral administration of oseltamivir are characterized by mean ± SD bioavailability of 79 ± 12%, apparent clearance of 25.3 ± 7.0 L/h, an elimination half-life of 7.4 ± 2.5 hours and an apparent terminal volume of distribution of 267 ± 122 L.","Oseltamivir in seasonal, avian H5N1 and pandemic 2009 A/H1N1 influenza: pharmacokinetic and pharmacodynamic characteristics. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20923248/),[l] / [h],25.3,84463,DB00198,Oseltamivir
,20923248,elimination half-life,"According to the currently available literature, the pharmacokinetics of oseltamivir carboxylate after oral administration of oseltamivir are characterized by mean ± SD bioavailability of 79 ± 12%, apparent clearance of 25.3 ± 7.0 L/h, an elimination half-life of 7.4 ± 2.5 hours and an apparent terminal volume of distribution of 267 ± 122 L.","Oseltamivir in seasonal, avian H5N1 and pandemic 2009 A/H1N1 influenza: pharmacokinetic and pharmacodynamic characteristics. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20923248/),h,7.4,84464,DB00198,Oseltamivir
,20923248,apparent terminal volume of distribution,"According to the currently available literature, the pharmacokinetics of oseltamivir carboxylate after oral administration of oseltamivir are characterized by mean ± SD bioavailability of 79 ± 12%, apparent clearance of 25.3 ± 7.0 L/h, an elimination half-life of 7.4 ± 2.5 hours and an apparent terminal volume of distribution of 267 ± 122 L.","Oseltamivir in seasonal, avian H5N1 and pandemic 2009 A/H1N1 influenza: pharmacokinetic and pharmacodynamic characteristics. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20923248/),l,267,84465,DB00198,Oseltamivir
,20923248,maximum plasma concentration,"A maximum plasma concentration of 342 ± 83 μg/L, a time to reach the maximum plasma concentration of 4.2 ± 1.1 hours, a trough plasma concentration of 168 ± 32 μg/L and an area under the plasma concentration-time curve from 0 to 24 hours of 6110 ± 1330 μg · h/L for a 75 mg twice-daily regimen were derived from literature data.","Oseltamivir in seasonal, avian H5N1 and pandemic 2009 A/H1N1 influenza: pharmacokinetic and pharmacodynamic characteristics. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20923248/),[μg] / [l],342,84466,DB00198,Oseltamivir
,20923248,time to reach the maximum plasma concentration,"A maximum plasma concentration of 342 ± 83 μg/L, a time to reach the maximum plasma concentration of 4.2 ± 1.1 hours, a trough plasma concentration of 168 ± 32 μg/L and an area under the plasma concentration-time curve from 0 to 24 hours of 6110 ± 1330 μg · h/L for a 75 mg twice-daily regimen were derived from literature data.","Oseltamivir in seasonal, avian H5N1 and pandemic 2009 A/H1N1 influenza: pharmacokinetic and pharmacodynamic characteristics. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20923248/),h,4.2,84467,DB00198,Oseltamivir
,20923248,trough plasma concentration,"A maximum plasma concentration of 342 ± 83 μg/L, a time to reach the maximum plasma concentration of 4.2 ± 1.1 hours, a trough plasma concentration of 168 ± 32 μg/L and an area under the plasma concentration-time curve from 0 to 24 hours of 6110 ± 1330 μg · h/L for a 75 mg twice-daily regimen were derived from literature data.","Oseltamivir in seasonal, avian H5N1 and pandemic 2009 A/H1N1 influenza: pharmacokinetic and pharmacodynamic characteristics. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20923248/),[μg] / [l],168,84468,DB00198,Oseltamivir
,20923248,area under the plasma concentration-time curve from 0 to 24 hours,"A maximum plasma concentration of 342 ± 83 μg/L, a time to reach the maximum plasma concentration of 4.2 ± 1.1 hours, a trough plasma concentration of 168 ± 32 μg/L and an area under the plasma concentration-time curve from 0 to 24 hours of 6110 ± 1330 μg · h/L for a 75 mg twice-daily regimen were derived from literature data.","Oseltamivir in seasonal, avian H5N1 and pandemic 2009 A/H1N1 influenza: pharmacokinetic and pharmacodynamic characteristics. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20923248/),[h·μg] / [l],6110,84469,DB00198,Oseltamivir
,27426925,fetal transfer rates,"Following 3 h of perfusion, the fetal transfer rates of OP and its metabolite OC were 12.39%±3.26%, 10.17%±2.03%, respectively.",Transplacental transfer of oseltamivir phosphate and its metabolite oseltamivir carboxylate using the ex vivo human placenta perfusion model in Chinese Hans population. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27426925/),%,12.39,93979,DB00198,Oseltamivir
,27426925,fetal transfer rates,"Following 3 h of perfusion, the fetal transfer rates of OP and its metabolite OC were 12.39%±3.26%, 10.17%±2.03%, respectively.",Transplacental transfer of oseltamivir phosphate and its metabolite oseltamivir carboxylate using the ex vivo human placenta perfusion model in Chinese Hans population. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27426925/),%,10.17,93980,DB00198,Oseltamivir
,27426925,clearance index,"The clearance indexes of OP and OC were 0.36 ± 0.11 and 0.29 ± 0.06, respectively.",Transplacental transfer of oseltamivir phosphate and its metabolite oseltamivir carboxylate using the ex vivo human placenta perfusion model in Chinese Hans population. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27426925/),,0.36,93981,DB00198,Oseltamivir
,27426925,clearance index,"The clearance indexes of OP and OC were 0.36 ± 0.11 and 0.29 ± 0.06, respectively.",Transplacental transfer of oseltamivir phosphate and its metabolite oseltamivir carboxylate using the ex vivo human placenta perfusion model in Chinese Hans population. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27426925/),,0.29,93982,DB00198,Oseltamivir
,27596232,AUC,"This dose range produced a target oseltamivir carboxylate plasma concentration in excess of the proposed 12-h target AUC of 3800 ng h/mL, selected from earlier studies to avert resistance.",Pharmacokinetics of oseltamivir in infants under the age of 1 year. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27596232/),[h·ng] / [ml],3800,99910,DB00198,Oseltamivir
,27596232,AUC,"In general agreement with earlier data, these doses produced a target oseltamivir carboxylate plasma exposure in excess of the proposed 12-h target exposure of AUC equal to 3800 ng h/mL in two patients.",Pharmacokinetics of oseltamivir in infants under the age of 1 year. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27596232/),[h·ng] / [ml],3800,99911,DB00198,Oseltamivir
,12910331,body weight normalized oral clearance,"Mean body weight normalized oral clearance of oseltamivir and its carboxylate in younger subjects aged 1-2 years (259 ml/min/kg and 12.2 ml/min/kg) were, respectively, 52% and 30% higher than those in older subjects aged 3-5 years (170 ml/min/kg and 9.4 ml/min/kg).",Pharmacokinetics of anti-influenza prodrug oseltamivir in children aged 1-5 years. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12910331/),[ml] / [kg·min],259,100863,DB00198,Oseltamivir
,12910331,body weight normalized oral clearance,"Mean body weight normalized oral clearance of oseltamivir and its carboxylate in younger subjects aged 1-2 years (259 ml/min/kg and 12.2 ml/min/kg) were, respectively, 52% and 30% higher than those in older subjects aged 3-5 years (170 ml/min/kg and 9.4 ml/min/kg).",Pharmacokinetics of anti-influenza prodrug oseltamivir in children aged 1-5 years. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12910331/),[ml] / [kg·min],12.2,100864,DB00198,Oseltamivir
,12910331,body weight normalized oral clearance,"Mean body weight normalized oral clearance of oseltamivir and its carboxylate in younger subjects aged 1-2 years (259 ml/min/kg and 12.2 ml/min/kg) were, respectively, 52% and 30% higher than those in older subjects aged 3-5 years (170 ml/min/kg and 9.4 ml/min/kg).",Pharmacokinetics of anti-influenza prodrug oseltamivir in children aged 1-5 years. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12910331/),[ml] / [kg·min],170,100865,DB00198,Oseltamivir
,12910331,body weight normalized oral clearance,"Mean body weight normalized oral clearance of oseltamivir and its carboxylate in younger subjects aged 1-2 years (259 ml/min/kg and 12.2 ml/min/kg) were, respectively, 52% and 30% higher than those in older subjects aged 3-5 years (170 ml/min/kg and 9.4 ml/min/kg).",Pharmacokinetics of anti-influenza prodrug oseltamivir in children aged 1-5 years. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12910331/),[ml] / [kg·min],9.4,100866,DB00198,Oseltamivir
,23118670,area under the plasma concentration time curves for the 12-hour dosing interval (AUC(0-12)),"The patient's oseltamivir and oseltamivir carboxylate area under the plasma concentration time curves for the 12-hour dosing interval (AUC(0-12)) were 30.5 and 905 ng/mLhr, respectively.",The pharmacokinetics of oseltamivir and oseltamivir carboxylate in a critically ill pediatric patient receiving extracorporeal membrane oxygenation and continuous venovenous hemodialysis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23118670/),[ng] / [mlhr],30.5,104790,DB00198,Oseltamivir
,23118670,area under the plasma concentration time curves for the 12-hour dosing interval (AUC(0-12)),"The patient's oseltamivir and oseltamivir carboxylate area under the plasma concentration time curves for the 12-hour dosing interval (AUC(0-12)) were 30.5 and 905 ng/mLhr, respectively.",The pharmacokinetics of oseltamivir and oseltamivir carboxylate in a critically ill pediatric patient receiving extracorporeal membrane oxygenation and continuous venovenous hemodialysis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23118670/),[ng] / [mlhr],905,104791,DB00198,Oseltamivir
,23118670,Drug clearance,Drug clearance by CVVHD was 31.6 mL/min for oseltamivir and 26.9 mL/min for oseltamivir carboxylate.,The pharmacokinetics of oseltamivir and oseltamivir carboxylate in a critically ill pediatric patient receiving extracorporeal membrane oxygenation and continuous venovenous hemodialysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23118670/),[ml] / [min],31.6,104792,DB00198,Oseltamivir
,23118670,Drug clearance,Drug clearance by CVVHD was 31.6 mL/min for oseltamivir and 26.9 mL/min for oseltamivir carboxylate.,The pharmacokinetics of oseltamivir and oseltamivir carboxylate in a critically ill pediatric patient receiving extracorporeal membrane oxygenation and continuous venovenous hemodialysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23118670/),[ml] / [min],26.9,104793,DB00198,Oseltamivir
,19721074,Brain-to-plasma exposure ratios,Brain-to-plasma exposure ratios were approximately 0.2 for oseltamivir and 0.01 for oseltamivir carboxylate.,Nonclinical pharmacokinetics of oseltamivir and oseltamivir carboxylate in the central nervous system. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19721074/),,0.2,108578,DB00198,Oseltamivir
,19721074,Brain-to-plasma exposure ratios,Brain-to-plasma exposure ratios were approximately 0.2 for oseltamivir and 0.01 for oseltamivir carboxylate.,Nonclinical pharmacokinetics of oseltamivir and oseltamivir carboxylate in the central nervous system. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19721074/),,0.01,108579,DB00198,Oseltamivir
,16799169,C(max),"In HD patients, the C(max) for oseltamivir carboxylate after single and repeated dosing were 943 and 1120 ng/ml, respectively.",The pharmacokinetics and tolerability of oseltamivir suspension in patients on haemodialysis and continuous ambulatory peritoneal dialysis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16799169/),[ng] / [ml],943,109582,DB00198,Oseltamivir
,16799169,C(max),"In HD patients, the C(max) for oseltamivir carboxylate after single and repeated dosing were 943 and 1120 ng/ml, respectively.",The pharmacokinetics and tolerability of oseltamivir suspension in patients on haemodialysis and continuous ambulatory peritoneal dialysis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16799169/),[ng] / [ml],1120,109583,DB00198,Oseltamivir
,16799169,AUC(0-42),The mean AUC(0-42) was 31 600 ng h/ml for days 1-5 and 38 200 ng h/ml for days 38-43.,The pharmacokinetics and tolerability of oseltamivir suspension in patients on haemodialysis and continuous ambulatory peritoneal dialysis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16799169/),[h·ng] / [ml],31 600,109584,DB00198,Oseltamivir
,16799169,AUC(0-42),The mean AUC(0-42) was 31 600 ng h/ml for days 1-5 and 38 200 ng h/ml for days 38-43.,The pharmacokinetics and tolerability of oseltamivir suspension in patients on haemodialysis and continuous ambulatory peritoneal dialysis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16799169/),[h·ng] / [ml],38 200,109585,DB00198,Oseltamivir
,16799169,C(max),"Similarly, in CAPD patients, mean C(max) after the first and sixth doses were 885 and 849 ng/ml, respectively.",The pharmacokinetics and tolerability of oseltamivir suspension in patients on haemodialysis and continuous ambulatory peritoneal dialysis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16799169/),[ng] / [ml],885,109586,DB00198,Oseltamivir
,16799169,C(max),"Similarly, in CAPD patients, mean C(max) after the first and sixth doses were 885 and 849 ng/ml, respectively.",The pharmacokinetics and tolerability of oseltamivir suspension in patients on haemodialysis and continuous ambulatory peritoneal dialysis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16799169/),[ng] / [ml],849,109587,DB00198,Oseltamivir
,16799169,AUC(0-48),"The mean AUC(0-48) values for days 1-6 and days 36-43 were 33 400 and 32 400 ng h/ml, respectively.",The pharmacokinetics and tolerability of oseltamivir suspension in patients on haemodialysis and continuous ambulatory peritoneal dialysis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16799169/),[h·ng] / [ml],33 400,109588,DB00198,Oseltamivir
,16799169,AUC(0-48),"The mean AUC(0-48) values for days 1-6 and days 36-43 were 33 400 and 32 400 ng h/ml, respectively.",The pharmacokinetics and tolerability of oseltamivir suspension in patients on haemodialysis and continuous ambulatory peritoneal dialysis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16799169/),[h·ng] / [ml],32 400,109589,DB00198,Oseltamivir
<,9303391,Ki,GS4071 is a novel potent inhibitor of influenza neuraminidase (Ki < 1 nM) with low (< 5%) oral bioavailability in animals.,"Penetration of GS4071, a novel influenza neuraminidase inhibitor, into rat bronchoalveolar lining fluid following oral administration of the prodrug GS4104. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9303391/),nM,1,110367,DB00198,Oseltamivir
,20845365,flow-rate,"The procedure for sample preparation includes a simple SPE extraction procedure coupled with a Chromatopack C(18) column (50 × 3.0 mm, i.d., 3.0 µm) with isocratic elution at a flow-rate of 0.600 mL /min and acyclovir was used as the internal standard.",Development and validation of a high-throughput and robust LC-MS/MS with electrospray ionization method for simultaneous quantitation of oseltamivir phosphate and its oseltamivir carboxylate metabolite in human plasma for pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20845365/),[ml] / [min],0.600,113424,DB00198,Oseltamivir
,20845365,recovery,"The recovery was 68.72, 70.66 and 71.59% for OP, OC and IS, respectively.",Development and validation of a high-throughput and robust LC-MS/MS with electrospray ionization method for simultaneous quantitation of oseltamivir phosphate and its oseltamivir carboxylate metabolite in human plasma for pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20845365/),%,68.72,113425,DB00198,Oseltamivir
,20845365,recovery,"The recovery was 68.72, 70.66 and 71.59% for OP, OC and IS, respectively.",Development and validation of a high-throughput and robust LC-MS/MS with electrospray ionization method for simultaneous quantitation of oseltamivir phosphate and its oseltamivir carboxylate metabolite in human plasma for pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20845365/),%,70.66,113426,DB00198,Oseltamivir
,20845365,recovery,"The recovery was 68.72, 70.66 and 71.59% for OP, OC and IS, respectively.",Development and validation of a high-throughput and robust LC-MS/MS with electrospray ionization method for simultaneous quantitation of oseltamivir phosphate and its oseltamivir carboxylate metabolite in human plasma for pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20845365/),%,71.59,113427,DB00198,Oseltamivir
,20845365,Total run time,Total run time was only 1.0 min.,Development and validation of a high-throughput and robust LC-MS/MS with electrospray ionization method for simultaneous quantitation of oseltamivir phosphate and its oseltamivir carboxylate metabolite in human plasma for pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20845365/),min,1.0,113428,DB00198,Oseltamivir
,32533654,elimination half-life,"The maximum plasma concentrations of BXA were observed at 1.50 and 2.00 hours with the two BXM doses, which then declined with an elimination half-life of 6.91 and 4.44 hours, respectively.",The antiviral effects of baloxavir marboxil against influenza A virus infection in ferrets. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/32533654/),h,6.91,116975,DB00198,Oseltamivir
,32533654,elimination half-life,"The maximum plasma concentrations of BXA were observed at 1.50 and 2.00 hours with the two BXM doses, which then declined with an elimination half-life of 6.91 and 4.44 hours, respectively.",The antiviral effects of baloxavir marboxil against influenza A virus infection in ferrets. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/32533654/),h,4.44,116976,DB00198,Oseltamivir
,31660381,time to cessation of,"Median time to cessation of viral shedding was similar with triple-dose and conventional-dose oseltamivir (150.7 vs 157.1 hours, respectively); median time to alleviation of baseline fever was longer with conventional-dose oseltamivir (28.4 vs 11.3 hours).",Pharmacokinetics and Pharmacodynamics of Conventional-Dose vs Triple-Dose Oseltamivir in Severely Immunocompromised Children With Influenza. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31660381/),h,150.7,122636,DB00198,Oseltamivir
,31660381,time to cessation of,"Median time to cessation of viral shedding was similar with triple-dose and conventional-dose oseltamivir (150.7 vs 157.1 hours, respectively); median time to alleviation of baseline fever was longer with conventional-dose oseltamivir (28.4 vs 11.3 hours).",Pharmacokinetics and Pharmacodynamics of Conventional-Dose vs Triple-Dose Oseltamivir in Severely Immunocompromised Children With Influenza. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31660381/),h,157.1,122637,DB00198,Oseltamivir
,31660381,time to alleviation,"Median time to cessation of viral shedding was similar with triple-dose and conventional-dose oseltamivir (150.7 vs 157.1 hours, respectively); median time to alleviation of baseline fever was longer with conventional-dose oseltamivir (28.4 vs 11.3 hours).",Pharmacokinetics and Pharmacodynamics of Conventional-Dose vs Triple-Dose Oseltamivir in Severely Immunocompromised Children With Influenza. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31660381/),h,28.4,122638,DB00198,Oseltamivir
,31660381,time to alleviation,"Median time to cessation of viral shedding was similar with triple-dose and conventional-dose oseltamivir (150.7 vs 157.1 hours, respectively); median time to alleviation of baseline fever was longer with conventional-dose oseltamivir (28.4 vs 11.3 hours).",Pharmacokinetics and Pharmacodynamics of Conventional-Dose vs Triple-Dose Oseltamivir in Severely Immunocompromised Children With Influenza. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31660381/),h,11.3,122639,DB00198,Oseltamivir
,26042486,AUClast),"Individual plasma oseltamivir carboxylate exposures (AUClast) ranged from 1,700 to 11,500 h x ng/mL.",Pharmacokinetics and safety of intravenous oseltamivir in infants and children in open-label studies. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26042486/),[h·ng] / [ml],"1,700 to 11,500",125201,DB00198,Oseltamivir
,24046309,Trough OC levels,Trough OC levels were higher in the 150-mg group (501.0 ± 237.0 vs 342.6 ± 192.7 ng/mL).,A prospective intervention study on higher-dose oseltamivir treatment in adults hospitalized with influenza a and B infections. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24046309/),[ng] / [ml],501.0,129071,DB00198,Oseltamivir
,24046309,Trough OC levels,Trough OC levels were higher in the 150-mg group (501.0 ± 237.0 vs 342.6 ± 192.7 ng/mL).,A prospective intervention study on higher-dose oseltamivir treatment in adults hospitalized with influenza a and B infections. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24046309/),[ng] / [ml],342.6,129072,DB00198,Oseltamivir
,19364864,EC(50)s,The dose-ranging study showed that the EC(50)s for oseltamivir carboxylate for the A/Sydney/5/97 strain of influenza virus was about 1.0 ng/ml.,Prediction of the pharmacodynamically linked variable of oseltamivir carboxylate for influenza A virus using an in vitro hollow-fiber infection model system. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19364864/),[ng] / [ml],1.0,130915,DB00198,Oseltamivir
,21263045,half-life,A clinical 2.5-h half-life and an artificially prolonged 8-h half-life were simulated for zanamivir.,Effect of half-life on the pharmacodynamic index of zanamivir against influenza virus delineated by a mathematical model. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21263045/),h,2.5,133938,DB00198,Oseltamivir
,21263045,half-life,A clinical 2.5-h half-life and an artificially prolonged 8-h half-life were simulated for zanamivir.,Effect of half-life on the pharmacodynamic index of zanamivir against influenza virus delineated by a mathematical model. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21263045/),h,8,133939,DB00198,Oseltamivir
,21263045,50% inhibitory concentration [IC(50)],"Zanamivir inhibited viral release (50% inhibitory concentration [IC(50)], 0.0168 mg/liter; maximum extent of inhibition, 0.990).",Effect of half-life on the pharmacodynamic index of zanamivir against influenza virus delineated by a mathematical model. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21263045/),[mg] / [l],0.0168,133940,DB00198,Oseltamivir
,21263045,maximum extent of inhibition,"Zanamivir inhibited viral release (50% inhibitory concentration [IC(50)], 0.0168 mg/liter; maximum extent of inhibition, 0.990).",Effect of half-life on the pharmacodynamic index of zanamivir against influenza virus delineated by a mathematical model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21263045/),,0.990,133941,DB00198,Oseltamivir
,26460484,area under the plasma concentration-time curve 0-12 h,"Monte Carlo simulations were used to determine that administration of a 5.08 mg/kg dose of oseltamivir phosphate to ferret every 12 h for 5 days results in the same median OC area under the plasma concentration-time curve 0-12 h (i.e., 3220 mg h/mL) as that observed in humans during steady state at the approved dose of 75 mg twice daily for 5 days.",Oseltamivir Population Pharmacokinetics in the Ferret: Model Application for Pharmacokinetic/Pharmacodynamic Study Design. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26460484/),[h·mg] / [ml],3220,137068,DB00198,Oseltamivir
≥,33232871,minimum observed plasma trough concentration (Ctrough),The primary pharmacokinetic endpoint was the proportion of patients with a minimum observed plasma trough concentration (Ctrough) ≥20 mg/L at all measured time points after the second dose.,"Phase 2a, open-label, dose-escalating, multi-center pharmacokinetic study of favipiravir (T-705) in combination with oseltamivir in patients with severe influenza. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33232871/),[mg] / [l],20,144460,DB00198,Oseltamivir
≥,33232871,Ctrough,"Modeling demonstrated that less than 50% of patients achieved Ctrough ≥20 mg/L for >80% of the duration of treatment of the two dose regimens evaluated (18.8% and 42.1% of patients for low and high dose regimen, respectively).","Phase 2a, open-label, dose-escalating, multi-center pharmacokinetic study of favipiravir (T-705) in combination with oseltamivir in patients with severe influenza. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33232871/),[mg] / [l],20,144461,DB00198,Oseltamivir
,24299495,airflow rate,"It was found that the ratio of OP and liposomes (1:10), inlet temperature (110 °C) and airflow rate (2.3 mL/min) showed optimized physical properties of OP liposomes.",Development and evaluation of a dry powder formulation of liposome-encapsulated oseltamivir phosphate for inhalation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24299495/),,2,151829,DB00198,Oseltamivir
up to,24299495,cumulative release percentage,And the cumulative release percentage was up to 50% in 20 h.,Development and evaluation of a dry powder formulation of liposome-encapsulated oseltamivir phosphate for inhalation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24299495/),%,50,151830,DB00198,Oseltamivir
,23208833,maximum plasma concentration,"The median maximum plasma concentration and area under the plasma concentration-time curve for the 12-hour dosing interval (AUC(0-12) ) for the remaining 12 patients were 83.4 ng/ml and 216 ng•hour/ml, respectively, for oseltamivir and 2000 ng/ml and 21,500 ng•hour/ml, respectively, for oseltamivir carboxylate.",Pharmacokinetics of oseltamivir and oseltamivir carboxylate in critically ill patients receiving continuous venovenous hemodialysis and/or extracorporeal membrane oxygenation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23208833/),[ng] / [ml],83.4,155633,DB00198,Oseltamivir
,23208833,maximum plasma concentration,"The median maximum plasma concentration and area under the plasma concentration-time curve for the 12-hour dosing interval (AUC(0-12) ) for the remaining 12 patients were 83.4 ng/ml and 216 ng•hour/ml, respectively, for oseltamivir and 2000 ng/ml and 21,500 ng•hour/ml, respectively, for oseltamivir carboxylate.",Pharmacokinetics of oseltamivir and oseltamivir carboxylate in critically ill patients receiving continuous venovenous hemodialysis and/or extracorporeal membrane oxygenation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23208833/),[ng] / [ml],2000,155634,DB00198,Oseltamivir
,23208833,area under the plasma concentration-time curve for the 12-hour dosing interval (AUC(0-12) ),"The median maximum plasma concentration and area under the plasma concentration-time curve for the 12-hour dosing interval (AUC(0-12) ) for the remaining 12 patients were 83.4 ng/ml and 216 ng•hour/ml, respectively, for oseltamivir and 2000 ng/ml and 21,500 ng•hour/ml, respectively, for oseltamivir carboxylate.",Pharmacokinetics of oseltamivir and oseltamivir carboxylate in critically ill patients receiving continuous venovenous hemodialysis and/or extracorporeal membrane oxygenation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23208833/),[h·ng] / [ml],216,155635,DB00198,Oseltamivir
,23208833,area under the plasma concentration-time curve for the 12-hour dosing interval (AUC(0-12) ),"The median maximum plasma concentration and area under the plasma concentration-time curve for the 12-hour dosing interval (AUC(0-12) ) for the remaining 12 patients were 83.4 ng/ml and 216 ng•hour/ml, respectively, for oseltamivir and 2000 ng/ml and 21,500 ng•hour/ml, respectively, for oseltamivir carboxylate.",Pharmacokinetics of oseltamivir and oseltamivir carboxylate in critically ill patients receiving continuous venovenous hemodialysis and/or extracorporeal membrane oxygenation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23208833/),[h·ng] / [ml],"21,500",155636,DB00198,Oseltamivir
,23208833,clearance,Mean clearance due to CVVHD was 33.8 ml/minute for oseltamivir and 50.2 ml/minute for oseltamivir carboxylate.,Pharmacokinetics of oseltamivir and oseltamivir carboxylate in critically ill patients receiving continuous venovenous hemodialysis and/or extracorporeal membrane oxygenation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23208833/),[ml] / [min],33.8,155637,DB00198,Oseltamivir
,23208833,clearance,Mean clearance due to CVVHD was 33.8 ml/minute for oseltamivir and 50.2 ml/minute for oseltamivir carboxylate.,Pharmacokinetics of oseltamivir and oseltamivir carboxylate in critically ill patients receiving continuous venovenous hemodialysis and/or extracorporeal membrane oxygenation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23208833/),[ml] / [min],50.2,155638,DB00198,Oseltamivir
,9824240,limit of detection,The limit of detection for GS4071 was 20 ng/ml.,"High-performance liquid chromatographic determination of GS4071, a potent inhibitor of influenza neuraminidase, in plasma by precolumn fluorescence derivatization with naphthalenedialdehyde. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9824240/),[ng] / [ml],20,161183,DB00198,Oseltamivir
>,9824240,total recovery,The method was linear from 25 to 1600 ng/ml and the total recovery was >68% over this concentration range.,"High-performance liquid chromatographic determination of GS4071, a potent inhibitor of influenza neuraminidase, in plasma by precolumn fluorescence derivatization with naphthalenedialdehyde. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9824240/),%,68,161184,DB00198,Oseltamivir
,24729605,IC(50),"AV5080 exhibited high activity against influenza virus neuraminidase in vitro, with IC(50) values of 0.03 nM and 0.07 nM against the neuraminidase of A/Duck/Minnesota/1525/1981/H5N1 and A/Perth/265/2009/H1N1 (wild-type), respectively.",Novel oral anti-influenza drug candidate AV5080. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24729605/),nM,0.03,163033,DB00198,Oseltamivir
,24729605,IC(50),"AV5080 exhibited high activity against influenza virus neuraminidase in vitro, with IC(50) values of 0.03 nM and 0.07 nM against the neuraminidase of A/Duck/Minnesota/1525/1981/H5N1 and A/Perth/265/2009/H1N1 (wild-type), respectively.",Novel oral anti-influenza drug candidate AV5080. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24729605/),nM,0.07,163034,DB00198,Oseltamivir
lower,23009169,absolute oral bioavailability,The absolute oral bioavailability of these compounds was lower than 12%.,Development of oseltamivir phosphonate congeners as anti-influenza agents. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23009169/),%,12,171768,DB00198,Oseltamivir
,22564835,area under the curve (AUC(0-12)),"A physiologically parameterized pharmacokinetic model predicted typical day 1 area under the curve (AUC(0-12)) values of 1,966 and 2,484 μg · h/liter for neonates and infants of ≤ 37 weeks of postmenstrual age (PMA) and >37 weeks of PMA treated with 1 mg/kg of body weight and 2 mg/kg, respectively.",Oseltamivir pharmacokinetics and clinical experience in neonates and infants during an outbreak of H1N1 influenza A virus infection in a neonatal intensive care unit. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22564835/),[h·μg] / [l],"1,966",175573,DB00198,Oseltamivir
,22564835,area under the curve (AUC(0-12)),"A physiologically parameterized pharmacokinetic model predicted typical day 1 area under the curve (AUC(0-12)) values of 1,966 and 2,484 μg · h/liter for neonates and infants of ≤ 37 weeks of postmenstrual age (PMA) and >37 weeks of PMA treated with 1 mg/kg of body weight and 2 mg/kg, respectively.",Oseltamivir pharmacokinetics and clinical experience in neonates and infants during an outbreak of H1N1 influenza A virus infection in a neonatal intensive care unit. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22564835/),[h·μg] / [l],"2,484",175574,DB00198,Oseltamivir
,22564835,steady-state AUC(0-12),"The corresponding steady-state AUC(0-12) values were 3,670 and 4,559 μg · h/liter.",Oseltamivir pharmacokinetics and clinical experience in neonates and infants during an outbreak of H1N1 influenza A virus infection in a neonatal intensive care unit. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22564835/),[h·μg] / [l],"3,670",175575,DB00198,Oseltamivir
,22564835,steady-state AUC(0-12),"The corresponding steady-state AUC(0-12) values were 3,670 and 4,559 μg · h/liter.",Oseltamivir pharmacokinetics and clinical experience in neonates and infants during an outbreak of H1N1 influenza A virus infection in a neonatal intensive care unit. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22564835/),[h·μg] / [l],"4,559",175576,DB00198,Oseltamivir
,28807912,half-life,Serum PK was linear with a half-life of ∼23 days.,"Phase 2 Randomized Trial of the Safety and Efficacy of MHAA4549A, a Broadly Neutralizing Monoclonal Antibody, in a Human Influenza A Virus Challenge Model. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28807912/),d,∼23,176363,DB00198,Oseltamivir
,18559644,steady-state apparent oral clearance,"The steady-state apparent oral clearance of oseltamivir carboxylate was significantly less in groups 2 (7.4 liters/h; 90% CI, 6.08 to 8.71) and 3 (7.19 liters/h; 90% CI, 6.41 to 7.98) than in group 1 (9.75 liters/h; 90% CI, 6.91 to 12.60) (P < 0.05 for both comparisons by analysis of variance).",Pharmacokinetics and tolerability of oseltamivir combined with probenecid. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18559644/),[l] / [h],7.4,193862,DB00198,Oseltamivir
,18559644,steady-state apparent oral clearance,"The steady-state apparent oral clearance of oseltamivir carboxylate was significantly less in groups 2 (7.4 liters/h; 90% CI, 6.08 to 8.71) and 3 (7.19 liters/h; 90% CI, 6.41 to 7.98) than in group 1 (9.75 liters/h; 90% CI, 6.91 to 12.60) (P < 0.05 for both comparisons by analysis of variance).",Pharmacokinetics and tolerability of oseltamivir combined with probenecid. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18559644/),[l] / [h],7.19,193863,DB00198,Oseltamivir
,18559644,steady-state apparent oral clearance,"The steady-state apparent oral clearance of oseltamivir carboxylate was significantly less in groups 2 (7.4 liters/h; 90% CI, 6.08 to 8.71) and 3 (7.19 liters/h; 90% CI, 6.41 to 7.98) than in group 1 (9.75 liters/h; 90% CI, 6.91 to 12.60) (P < 0.05 for both comparisons by analysis of variance).",Pharmacokinetics and tolerability of oseltamivir combined with probenecid. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18559644/),[l] / [h],9.75,193864,DB00198,Oseltamivir
,18559644,concentration,"The (arithmetic) mean concentration at 48 h for group 2 was not significantly different from the mean concentration at 24 h for group 1 (42 +/- 76 and 81 +/- 54 ng/ml, respectively; P = 0.194), but the mean concentration at 48 h for group 3 was significantly less than the mean concentration at 24 h for group 1 (23 +/- 26 and 81 +/- 54 ng/ml, respectively; P = 0.012).",Pharmacokinetics and tolerability of oseltamivir combined with probenecid. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18559644/),ng,42,193865,DB00198,Oseltamivir
,18559644,concentration,"The (arithmetic) mean concentration at 48 h for group 2 was not significantly different from the mean concentration at 24 h for group 1 (42 +/- 76 and 81 +/- 54 ng/ml, respectively; P = 0.194), but the mean concentration at 48 h for group 3 was significantly less than the mean concentration at 24 h for group 1 (23 +/- 26 and 81 +/- 54 ng/ml, respectively; P = 0.012).",Pharmacokinetics and tolerability of oseltamivir combined with probenecid. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18559644/),ng,23,193866,DB00198,Oseltamivir
,18559644,concentration,"The (arithmetic) mean concentration at 48 h for group 2 was not significantly different from the mean concentration at 24 h for group 1 (42 +/- 76 and 81 +/- 54 ng/ml, respectively; P = 0.194), but the mean concentration at 48 h for group 3 was significantly less than the mean concentration at 24 h for group 1 (23 +/- 26 and 81 +/- 54 ng/ml, respectively; P = 0.012).",Pharmacokinetics and tolerability of oseltamivir combined with probenecid. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18559644/),ng,81,193867,DB00198,Oseltamivir
,21670188,area under the curve from time zero to infinity (AUC),"Means ± standard deviations of the area under the curve from time zero to infinity (AUC) were 173 ± 58 μg · h/liter for oseltamivir and 2,256 ± 394 μg · h/liter for OC.",Pharmacokinetics and diffusion into sputum of oseltamivir and oseltamivir carboxylate in adults with cystic fibrosis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21670188/),[h·μg] / [l],173,206810,DB00198,Oseltamivir
,21670188,area under the curve from time zero to infinity (AUC),"Means ± standard deviations of the area under the curve from time zero to infinity (AUC) were 173 ± 58 μg · h/liter for oseltamivir and 2,256 ± 394 μg · h/liter for OC.",Pharmacokinetics and diffusion into sputum of oseltamivir and oseltamivir carboxylate in adults with cystic fibrosis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21670188/),[h·μg] / [l],"2,256",206811,DB00198,Oseltamivir
,32872397,distribution,"Shikimic acid exhibited bi-exponential decay after intravenous dosing, with a rapid distribution (5.57 h-1) up to 1 h followed by slow elimination (0.78 h-1).",Pharmacokinetics of Shikimic Acid Following Intragastric and Intravenous Administrations in Rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32872397/),1/[h],5.57,210509,DB00198,Oseltamivir
,32872397,elimination,"Shikimic acid exhibited bi-exponential decay after intravenous dosing, with a rapid distribution (5.57 h-1) up to 1 h followed by slow elimination (0.78 h-1).",Pharmacokinetics of Shikimic Acid Following Intragastric and Intravenous Administrations in Rats. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32872397/),1/[h],0.78,210510,DB00198,Oseltamivir
,32872397,steady state distribution,"The steady state distribution and clearance volumes were 5.17 and 1.79 L/h/kg, respectively.",Pharmacokinetics of Shikimic Acid Following Intragastric and Intravenous Administrations in Rats. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32872397/),[l] / [h·kg],5.17,210511,DB00198,Oseltamivir
,32872397,clearance volumes,"The steady state distribution and clearance volumes were 5.17 and 1.79 L/h/kg, respectively.",Pharmacokinetics of Shikimic Acid Following Intragastric and Intravenous Administrations in Rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32872397/),[l] / [h·kg],1.79,210512,DB00198,Oseltamivir
,32872397,half-life,"After intragastric administration, the shikimic acid level peaked at about 3 h, and the material then disappeared mono-exponentially with a half-life of 1.3 h.",Pharmacokinetics of Shikimic Acid Following Intragastric and Intravenous Administrations in Rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32872397/),h,1.3,210513,DB00198,Oseltamivir
,32872397,absolute oral bioavailability,The absolute oral bioavailability was about 10% in rats.,Pharmacokinetics of Shikimic Acid Following Intragastric and Intravenous Administrations in Rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32872397/),%,10,210514,DB00198,Oseltamivir
,19104028,conversion level,"Oseltamivir phosphate (OS) was rapidly and completely absorbed and converted (median conversion level, 93%) to the active carboxylate metabolite.",Pharmacokinetics of high-dose oseltamivir in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19104028/),%,93,215577,DB00198,Oseltamivir
,19104028,elimination half-lives,Median elimination half-lives (and 95% confidence intervals [CI]) were 1.0 h (0.9 to 1.1 h) for OS and 5.1 h (4.7 to 5.7 h) for oseltamivir carboxylate (OC).,Pharmacokinetics of high-dose oseltamivir in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19104028/),h,1.0,215578,DB00198,Oseltamivir
,19104028,elimination half-lives,Median elimination half-lives (and 95% confidence intervals [CI]) were 1.0 h (0.9 to 1.1 h) for OS and 5.1 h (4.7 to 5.7 h) for oseltamivir carboxylate (OC).,Pharmacokinetics of high-dose oseltamivir in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19104028/),h,5.1,215579,DB00198,Oseltamivir
,21958869,FTR,"The median FTR of oseltamivir phosphate was 8.5% (range, 5.0-11.6%) and the median CI was 0.3 (range, 0.2-0.6).",Transplacental transfer of oseltamivir and its metabolite using the human perfused placental cotyledon model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21958869/),%,8,221788,DB00198,Oseltamivir
,23669386,IC(50)],"Healthy volunteers in studies 1 and 2 were experimentally infected with influenza A/Texas (the concentration of neuraminidase inhibitor which reduced neuraminidase activity by 50% [IC(50)] = 0.18 nM) or B/Yamagata (IC(50) = 16.76 nM), respectively.",Pharmacokinetic-pharmacodynamic determinants of oseltamivir efficacy using data from phase 2 inoculation studies. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23669386/),nM,0.18,225275,DB00198,Oseltamivir
,23669386,IC(50),"Healthy volunteers in studies 1 and 2 were experimentally infected with influenza A/Texas (the concentration of neuraminidase inhibitor which reduced neuraminidase activity by 50% [IC(50)] = 0.18 nM) or B/Yamagata (IC(50) = 16.76 nM), respectively.",Pharmacokinetic-pharmacodynamic determinants of oseltamivir efficacy using data from phase 2 inoculation studies. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23669386/),nM,16.76,225276,DB00198,Oseltamivir
,23669386,AUC(0-24),"The upper OC AUC(0-24) threshold (~14,000 ng · h/ml) was similar among these endpoints.",Pharmacokinetic-pharmacodynamic determinants of oseltamivir efficacy using data from phase 2 inoculation studies. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23669386/),[h·ng] / [ml],"14,000",225277,DB00198,Oseltamivir
,30078836,peak plasma concentrations,"Oseltamivir in doses of 0.3, 3 and 30 mg/kg was intravenously infused over 10 min with an interval of 20 min, which provided peak plasma concentrations 1.4, 7.4 and 125.5 µg/mL, respectively.",Electropharmacological characterization of microminipigs as a laboratory animal using anti-influenza virus drug oseltamivir. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30078836/),[μg] / [ml],1.4,225341,DB00198,Oseltamivir
,30078836,peak plasma concentrations,"Oseltamivir in doses of 0.3, 3 and 30 mg/kg was intravenously infused over 10 min with an interval of 20 min, which provided peak plasma concentrations 1.4, 7.4 and 125.5 µg/mL, respectively.",Electropharmacological characterization of microminipigs as a laboratory animal using anti-influenza virus drug oseltamivir. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30078836/),[μg] / [ml],7.4,225342,DB00198,Oseltamivir
,30078836,peak plasma concentrations,"Oseltamivir in doses of 0.3, 3 and 30 mg/kg was intravenously infused over 10 min with an interval of 20 min, which provided peak plasma concentrations 1.4, 7.4 and 125.5 µg/mL, respectively.",Electropharmacological characterization of microminipigs as a laboratory animal using anti-influenza virus drug oseltamivir. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30078836/),[μg] / [ml],125.5,225343,DB00198,Oseltamivir
,23000242,peak width,The fast LC gradient further increases the sensitivity by narrowing the peak width (6-9s) and eluting the analytes at higher organic content.,Simple and sensitive assay for quantification of oseltamivir and its active metabolite oseltamivir carboxylate in human plasma using high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry: improved applicability to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23000242/),s,6-9,226013,DB00198,Oseltamivir
,26282419,clearance,Estimated OC clearance in the model was markedly faster during HD sessions (7.43 liters/min) than at other times (0.19 liter/min).,Investigating clinically adequate concentrations of oseltamivir carboxylate in end-stage renal disease patients undergoing hemodialysis using a population pharmacokinetic approach. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26282419/),[l] / [min],7.43,226049,DB00198,Oseltamivir
,26282419,clearance,Estimated OC clearance in the model was markedly faster during HD sessions (7.43 liters/min) than at other times (0.19 liter/min).,Investigating clinically adequate concentrations of oseltamivir carboxylate in end-stage renal disease patients undergoing hemodialysis using a population pharmacokinetic approach. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26282419/),[l] / [min],0.19,226050,DB00198,Oseltamivir
≤,24214317,plasma unbound inhibition constant,"We demonstrated the practical use of PBPK models to: (1) define transporter-mediated renal secretion, using plasma and urine data; (2) inform a change in the system-dependent parameter (≥10-fold reduction in the functional 'proximal tubule cells per gram kidney') in severe renal impairment that is responsible for the decreased secretory transport activities of test drugs; (3) derive an in vivo, plasma unbound inhibition constant of T up,b by probenecid (≤1 μM), based on observed drug interaction data; and (4) suggest a plausible mechanism of probenecid preferentially inhibiting T up,b in order to alleviate cidofovir-induced nephrotoxicity.","Towards quantitation of the effects of renal impairment and probenecid inhibition on kidney uptake and efflux transporters, using physiologically based pharmacokinetic modelling and simulations. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24214317/),μM,1,228531,DB00198,Oseltamivir
,23362894,clearance,"The median (range) clearance of oseltamivir carboxylate was 15.8 (4.8-36.6) l/hour, lower than the reported mean value of 21.5 l/hour in healthy adults.",Oseltamivir pharmacokinetics in critically ill adults receiving extracorporeal membrane oxygenation support. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23362894/),[l] / [h],15.8,236097,DB00198,Oseltamivir
,23362894,clearance,"The median (range) clearance of oseltamivir carboxylate was 15.8 (4.8-36.6) l/hour, lower than the reported mean value of 21.5 l/hour in healthy adults.",Oseltamivir pharmacokinetics in critically ill adults receiving extracorporeal membrane oxygenation support. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23362894/),[l] / [h],21.5,236098,DB00198,Oseltamivir
,23362894,steady state volume of distribution,"The median (range) steady state volume of distribution of oseltamivir carboxylate was 179 (61-436) litres, much greater than healthy adults but similar to previous reports in critically ill patients.",Oseltamivir pharmacokinetics in critically ill adults receiving extracorporeal membrane oxygenation support. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23362894/),l,179,236099,DB00198,Oseltamivir
,23362894,area under the curve,"Substantial 'between subject' variability in systemic exposure to oseltamivir carboxylate was revealed; median (range) area under the curve and Cmax were 4346 (644-13660) ng/hour/ml and 509 (54-1277) ng/ml, respectively.",Oseltamivir pharmacokinetics in critically ill adults receiving extracorporeal membrane oxygenation support. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23362894/),[ng] / [h·ml],4346,236100,DB00198,Oseltamivir
,23362894,Cmax,"Substantial 'between subject' variability in systemic exposure to oseltamivir carboxylate was revealed; median (range) area under the curve and Cmax were 4346 (644-13660) ng/hour/ml and 509 (54-1277) ng/ml, respectively.",Oseltamivir pharmacokinetics in critically ill adults receiving extracorporeal membrane oxygenation support. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23362894/),[ng] / [ml],509,236101,DB00198,Oseltamivir
,24422530,oral bioavailability,"Among different prodrug strategies pursued, a simple amidoxime ethyl ester (9) exhibited a superior PK profile with an oral bioavailability of 31% (rats), which is comparable to oseltamivir (36%).",Development of novel potent orally bioavailable oseltamivir derivatives active against resistant influenza A. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24422530/),%,31,248657,DB00198,Oseltamivir
,24422530,oral bioavailability,"Among different prodrug strategies pursued, a simple amidoxime ethyl ester (9) exhibited a superior PK profile with an oral bioavailability of 31% (rats), which is comparable to oseltamivir (36%).",Development of novel potent orally bioavailable oseltamivir derivatives active against resistant influenza A. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24422530/),%,36,248658,DB00198,Oseltamivir
,21700623,oral clearance (CL/F),"In the morbidly obese versus control subjects, respectively, the single-dose median oseltamivir oral clearance (CL/F) [840 (range 720-1640) L/h versus 580 (470-1800) L/h] was higher, the area under the curve from time zero to infinity (AUC(0-∞)) [89 (46-104) ng·h/mL versus 132 (42-160) ng·h/mL] was lower and the volume of distribution (V/F) [2320 (900-8210) L versus 1670 (700-7290) L] was unchanged.",Oseltamivir pharmacokinetics in morbid obesity (OPTIMO trial). ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21700623/),[l] / [h],840,257485,DB00198,Oseltamivir
,21700623,oral clearance (CL/F),"In the morbidly obese versus control subjects, respectively, the single-dose median oseltamivir oral clearance (CL/F) [840 (range 720-1640) L/h versus 580 (470-1800) L/h] was higher, the area under the curve from time zero to infinity (AUC(0-∞)) [89 (46-104) ng·h/mL versus 132 (42-160) ng·h/mL] was lower and the volume of distribution (V/F) [2320 (900-8210) L versus 1670 (700-7290) L] was unchanged.",Oseltamivir pharmacokinetics in morbid obesity (OPTIMO trial). ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21700623/),[l] / [h],580,257486,DB00198,Oseltamivir
,21700623,area under the curve from time zero to infinity (AUC(0-∞)),"In the morbidly obese versus control subjects, respectively, the single-dose median oseltamivir oral clearance (CL/F) [840 (range 720-1640) L/h versus 580 (470-1800) L/h] was higher, the area under the curve from time zero to infinity (AUC(0-∞)) [89 (46-104) ng·h/mL versus 132 (42-160) ng·h/mL] was lower and the volume of distribution (V/F) [2320 (900-8210) L versus 1670 (700-7290) L] was unchanged.",Oseltamivir pharmacokinetics in morbid obesity (OPTIMO trial). ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21700623/),[h·ng] / [ml],89,257487,DB00198,Oseltamivir
,21700623,area under the curve from time zero to infinity (AUC(0-∞)),"In the morbidly obese versus control subjects, respectively, the single-dose median oseltamivir oral clearance (CL/F) [840 (range 720-1640) L/h versus 580 (470-1800) L/h] was higher, the area under the curve from time zero to infinity (AUC(0-∞)) [89 (46-104) ng·h/mL versus 132 (42-160) ng·h/mL] was lower and the volume of distribution (V/F) [2320 (900-8210) L versus 1670 (700-7290) L] was unchanged.",Oseltamivir pharmacokinetics in morbid obesity (OPTIMO trial). ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21700623/),[h·ng] / [ml],132,257488,DB00198,Oseltamivir
,21700623,volume of distribution (V/F),"In the morbidly obese versus control subjects, respectively, the single-dose median oseltamivir oral clearance (CL/F) [840 (range 720-1640) L/h versus 580 (470-1800) L/h] was higher, the area under the curve from time zero to infinity (AUC(0-∞)) [89 (46-104) ng·h/mL versus 132 (42-160) ng·h/mL] was lower and the volume of distribution (V/F) [2320 (900-8210) L versus 1670 (700-7290) L] was unchanged.",Oseltamivir pharmacokinetics in morbid obesity (OPTIMO trial). ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21700623/),l,2320,257489,DB00198,Oseltamivir
,21700623,volume of distribution (V/F),"In the morbidly obese versus control subjects, respectively, the single-dose median oseltamivir oral clearance (CL/F) [840 (range 720-1640) L/h versus 580 (470-1800) L/h] was higher, the area under the curve from time zero to infinity (AUC(0-∞)) [89 (46-104) ng·h/mL versus 132 (42-160) ng·h/mL] was lower and the volume of distribution (V/F) [2320 (900-8210) L versus 1670 (700-7290) L] was unchanged.",Oseltamivir pharmacokinetics in morbid obesity (OPTIMO trial). ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21700623/),l,1670,257490,DB00198,Oseltamivir
,21700623,CL/F,"In the morbidly obese versus control subjects, respectively, the single-dose median oseltamivir carboxylate CL/F [22 (17-40) L/h versus 23 (12-33) L/h], AUC(0-∞) [3100 (1700-4100) ng·h/mL versus 3000 (2100-5900) ng·h/mL] and V/F [200 (130-370) L versus 260 (150-430) L] were similar.",Oseltamivir pharmacokinetics in morbid obesity (OPTIMO trial). ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21700623/),[l] / [h],22,257491,DB00198,Oseltamivir
,21700623,CL/F,"In the morbidly obese versus control subjects, respectively, the single-dose median oseltamivir carboxylate CL/F [22 (17-40) L/h versus 23 (12-33) L/h], AUC(0-∞) [3100 (1700-4100) ng·h/mL versus 3000 (2100-5900) ng·h/mL] and V/F [200 (130-370) L versus 260 (150-430) L] were similar.",Oseltamivir pharmacokinetics in morbid obesity (OPTIMO trial). ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21700623/),[l] / [h],23,257492,DB00198,Oseltamivir
,21700623,AUC(0-∞),"In the morbidly obese versus control subjects, respectively, the single-dose median oseltamivir carboxylate CL/F [22 (17-40) L/h versus 23 (12-33) L/h], AUC(0-∞) [3100 (1700-4100) ng·h/mL versus 3000 (2100-5900) ng·h/mL] and V/F [200 (130-370) L versus 260 (150-430) L] were similar.",Oseltamivir pharmacokinetics in morbid obesity (OPTIMO trial). ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21700623/),[h·ng] / [ml],3100,257493,DB00198,Oseltamivir
,21700623,AUC(0-∞),"In the morbidly obese versus control subjects, respectively, the single-dose median oseltamivir carboxylate CL/F [22 (17-40) L/h versus 23 (12-33) L/h], AUC(0-∞) [3100 (1700-4100) ng·h/mL versus 3000 (2100-5900) ng·h/mL] and V/F [200 (130-370) L versus 260 (150-430) L] were similar.",Oseltamivir pharmacokinetics in morbid obesity (OPTIMO trial). ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21700623/),[h·ng] / [ml],3000,257494,DB00198,Oseltamivir
,21700623,V/F,"In the morbidly obese versus control subjects, respectively, the single-dose median oseltamivir carboxylate CL/F [22 (17-40) L/h versus 23 (12-33) L/h], AUC(0-∞) [3100 (1700-4100) ng·h/mL versus 3000 (2100-5900) ng·h/mL] and V/F [200 (130-370) L versus 260 (150-430) L] were similar.",Oseltamivir pharmacokinetics in morbid obesity (OPTIMO trial). ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21700623/),l,200,257495,DB00198,Oseltamivir
,21700623,V/F,"In the morbidly obese versus control subjects, respectively, the single-dose median oseltamivir carboxylate CL/F [22 (17-40) L/h versus 23 (12-33) L/h], AUC(0-∞) [3100 (1700-4100) ng·h/mL versus 3000 (2100-5900) ng·h/mL] and V/F [200 (130-370) L versus 260 (150-430) L] were similar.",Oseltamivir pharmacokinetics in morbid obesity (OPTIMO trial). ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21700623/),l,260,257496,DB00198,Oseltamivir
,22354159,Cmax,OC Cmax (1029 ± 478 ng/mL) and area under the curve (9.00 ± 4.52 mcg·h/mL) for patients on ECMO with preserved renal function were comparable with those of healthy volunteers or noncritically ill patients.,Impact of extracorporeal membrane oxygenation and continuous venovenous hemodiafiltration on the pharmacokinetics of oseltamivir carboxylate in critically ill patients with pandemic (H1N1) influenza. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22354159/),[ng] / [ml],1029,258298,DB00198,Oseltamivir
,22354159,area under the curve,OC Cmax (1029 ± 478 ng/mL) and area under the curve (9.00 ± 4.52 mcg·h/mL) for patients on ECMO with preserved renal function were comparable with those of healthy volunteers or noncritically ill patients.,Impact of extracorporeal membrane oxygenation and continuous venovenous hemodiafiltration on the pharmacokinetics of oseltamivir carboxylate in critically ill patients with pandemic (H1N1) influenza. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22354159/),[h·mcg] / [ml],9.00,258299,DB00198,Oseltamivir
,18676886,observed maximum concentrations [C(max)],"Oseltamivir and OC concentrations in CSF were low (mean of observed maximum concentrations [C(max)], 2.4 ng/ml [oseltamivir] and 19.0 ng/ml [OC]) versus those in plasma (mean C(max), 115 ng/ml [oseltamivir] and 544 ng/ml [OC]), with corresponding C(max) CSF/plasma ratios of 2.1% (oseltamivir) and 3.5% (OC).",Low penetration of oseltamivir and its carboxylate into cerebrospinal fluid in healthy Japanese and Caucasian volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18676886/),[ng] / [ml],2.4,265095,DB00198,Oseltamivir
,18676886,observed maximum concentrations [C(max)],"Oseltamivir and OC concentrations in CSF were low (mean of observed maximum concentrations [C(max)], 2.4 ng/ml [oseltamivir] and 19.0 ng/ml [OC]) versus those in plasma (mean C(max), 115 ng/ml [oseltamivir] and 544 ng/ml [OC]), with corresponding C(max) CSF/plasma ratios of 2.1% (oseltamivir) and 3.5% (OC).",Low penetration of oseltamivir and its carboxylate into cerebrospinal fluid in healthy Japanese and Caucasian volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18676886/),[ng] / [ml],19.0,265096,DB00198,Oseltamivir
,18676886,C(max),"Oseltamivir and OC concentrations in CSF were low (mean of observed maximum concentrations [C(max)], 2.4 ng/ml [oseltamivir] and 19.0 ng/ml [OC]) versus those in plasma (mean C(max), 115 ng/ml [oseltamivir] and 544 ng/ml [OC]), with corresponding C(max) CSF/plasma ratios of 2.1% (oseltamivir) and 3.5% (OC).",Low penetration of oseltamivir and its carboxylate into cerebrospinal fluid in healthy Japanese and Caucasian volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18676886/),[ng] / [ml],115,265097,DB00198,Oseltamivir
,18676886,C(max),"Oseltamivir and OC concentrations in CSF were low (mean of observed maximum concentrations [C(max)], 2.4 ng/ml [oseltamivir] and 19.0 ng/ml [OC]) versus those in plasma (mean C(max), 115 ng/ml [oseltamivir] and 544 ng/ml [OC]), with corresponding C(max) CSF/plasma ratios of 2.1% (oseltamivir) and 3.5% (OC).",Low penetration of oseltamivir and its carboxylate into cerebrospinal fluid in healthy Japanese and Caucasian volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18676886/),[ng] / [ml],544,265098,DB00198,Oseltamivir
,18676886,area under the concentration-time curve,"Overall exposure to oseltamivir and OC in CSF was also comparatively low versus that in plasma (mean area under the concentration-time curve CSF/plasma ratio, 2.4% [oseltamivir] and 2.9% [OC]).",Low penetration of oseltamivir and its carboxylate into cerebrospinal fluid in healthy Japanese and Caucasian volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18676886/),%,2.4,265099,DB00198,Oseltamivir
,18676886,area under the concentration-time curve,"Overall exposure to oseltamivir and OC in CSF was also comparatively low versus that in plasma (mean area under the concentration-time curve CSF/plasma ratio, 2.4% [oseltamivir] and 2.9% [OC]).",Low penetration of oseltamivir and its carboxylate into cerebrospinal fluid in healthy Japanese and Caucasian volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18676886/),%,2.9,265100,DB00198,Oseltamivir
,28639229,terminal half-life,"MHAA4549A showed dose-proportional serum PKs with a long terminal half-life (approximately 21.9-24.6 days) and slow clearance (approximately 152-240 mL/day); however, nasopharyngeal swab PKs were not dose proportional.","Pharmacokinetics of MHAA4549A, an Anti-Influenza A Monoclonal Antibody, in Healthy Subjects Challenged with Influenza A Virus in a Phase IIa Randomized Trial. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28639229/),d,21.9-24.6,270340,DB00198,Oseltamivir
,28639229,clearance,"MHAA4549A showed dose-proportional serum PKs with a long terminal half-life (approximately 21.9-24.6 days) and slow clearance (approximately 152-240 mL/day); however, nasopharyngeal swab PKs were not dose proportional.","Pharmacokinetics of MHAA4549A, an Anti-Influenza A Monoclonal Antibody, in Healthy Subjects Challenged with Influenza A Virus in a Phase IIa Randomized Trial. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28639229/),[ml] / [d],152-240,270341,DB00198,Oseltamivir
,31957010,Hill coefficient,Half the adult OC clearance was reached at a PMA of 45.6 weeks (95% confidence interval (CI) 41.6-49.6) with a Hill coefficient of 2.35 (95% CI 1.67-3.04).,Mechanistic Population Pharmacokinetic Model of Oseltamivir and Oseltamivir Carboxylate Accounting for Physiological Changes to Predict Exposures in Neonates and Infants. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31957010/),,2.35,273597,DB00198,Oseltamivir
